Replies to post #255452 on Biotech Values

[Whalatane]

UNCY. Well the big issue is poor patient compliance with the existing binders . Patients generally hate them ...large , multiple pills per meal which often have to be chewed ( not swallowed ) so few of my wife's patients are at serum pho goals
So agree that financing is tight until FDA approved.
Note out today

Street View: According to analysts at H.C. Wainwright, who maintain a Buy rating and a $9.00 price target, the deficiency appears limited to a fill-finish subcontractor and does not involve safety or efficacy concerns with OLC itself. The firm believes the worst-case outcome would be a short delay, potentially resulting in a complete response letter (CRL) that pushes the timeline by three months. However, the analysts continue to project risk-adjusted peak revenue of $557 million in 2028 and view the long-term potential of the product as unchanged.
Management has secured $103 million in committed capital from accredited investors, contingent upon FDA approval. With $19.8 million in cash as of Q1 2025, the company has sufficient funds to continue operations while it prepares for commercialization.
As the FDA decision date approaches, Unicycive remains focused on resolving the vendor issue while advancing OLC as a differentiated treatment in a space with significant unmet need.

Kiwi